

Product Theater Schedule of Events

Please note some presentations are requesting pre-registration. Those links are provided in the session listings below if applicable.

Tuesday, September 8, 2020

2–2:45 pm EST

Intervening with Jakafi (ruxolitinib) to Achieve Durable Count Control: Real World Patient Case Discussion | Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea

Incyte

Please join us on Tuesday, September 8, 2020 from 2:00 PM – 2:45 PM ET for a theater presentation hosted by Incyte Corporation. Incyte, a global biopharmaceutical company based in Wilmington, Delaware, is a company founded on the premise that investment in good science and the rigorous pursuit of R&D excellence can translate into new medicines that can positively affect patients' lives.

3–3:45 pm EST

Advancements In The Treatment Of Lung Cancer

Genentech Tecentriq

REGISTER HERE: www.geniersvp.com/SGEN30908

Thursday, September 10, 2020

2–2:45 pm EST

The Only Approved Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Stemline Therapeutics

Join us for an overview of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a clinically aggressive and fatal hematologic malignancy that often presents with skin lesions. The program will aim to increase the understanding of BPDCN as well as educate on the efficacy, safety, dosing, and administration of the only approved treatment option for BPDCN.

Fertility Preservation: Options for the Oncology Patient

Walgreens/AllianceRx Walgreens Prime

Patients of childbearing age (and pediatric patients) who have been diagnosed with cancer may want to consider preserving their fertility and need to know their options. This presentation reviews the updated, currently approved and experimental treatments available for this patient population.

Objectives:

- Explain the emerging field of fertility preservation and oncofertility
- Identify some of the common concerns of individuals with a new cancer diagnosis when considering their reproductive potential
- Describe the biological effects that cancer treatment can have on various aspects of reproduction
- List the various technologies available for fertility preservation and have a general understanding of their applications
- Describe how medical professionals can facilitate needs of patients who are interested in preserving fertility

LONSURF® Oral Chemotherapy for Previously Treated Metastatic Colorectal, Gastric and Gastroesophageal Junction (GEJ) Cancers

This presentation is sponsored by Taiho Oncology.

Please join us for a virtual learning hall presentation theater and overview of LONSURF® (trifluridine and tipiracil) hosted by Taiho Oncology. Cyndy Simonson, MS, APRN-BC, AOCN from Duke University Health System, will discuss LONSURF® and provide key information regarding this oral chemotherapy. We hope you will join us for this engaging event.

A CDK 4 & 6 Inhibitor With Overall Survival Data for Women With HR+, HER2- Metastatic Breast Cancer, Including Those Likely To Do Worse © Lilly USA, LLC 2020. All rights reserved.

Join us to learn more about a CDK 4 & 6 inhibitor with overall survival data for women with HR+, HER2- metastatic breast cancer, including those likely to do worse.

3–3:45 pm EST

Treating Patients with Advanced Prostate Cancer: Metastatic and Non-Metastatic PC

Janssen-ERLEADA

Haydee Kapin, DNP, ARNU, BC, AOCN from the University of Miami, Sylvester Comprehensive Cancer Center Miami, FL will be presenting a live session about "Treating Patients with Advanced Prostate Cancer: Metastatic and Non-Metastatic PC